Introduction
Intravenous bisphosphonates and subcutaneous denosumab are potent antiresorptive agents widely used in the treatment of osteoporosis, Paget's disease and metastatic malignancy (1) . Several case reports have identified the risk of lifethreatening hypocalcaemia with these treatments (2-4), as highlighted by recent UKMHRA advice (5) . Vitamin D deficiency contributes to this risk and it is recommended that supplements are given where necessary. 
Local guidlines

Result of first audit cycle
95% non-compliance with 25OHD measurement guidelines
Result of second audit cycle
After the first audit, a standard of 85% compliance with guidelines was set as success threshold for the changes put in place. 
Comparison between audit cycles
Through the change effectors, we demonstrate an 80% improvement in the monitoring of 25OHD levels. Importantly, there was a 20% reduction in the number of patients with very low (<25 nmol/L) 25OHD levels. 
